title: A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation.
abstract: OBJECTIVE
  Our aim was to retrospectively investigate the data from our institute the response rate and outcome in patients with primary mediastinal B-cell lymphoma (PMBL) who received the rituximab in combination with CHOP (RCHOP) followed by autologous stem cell transplantation (ASCT) or RCHOP followed by involved field radiation therapy (IFRT).
  
  
  METHODS
  Sixty five patients with PMBL received RCHOP as first-line chemotherapy between January 2005 and December 2010. Forty of the 65 patients completed the planned subsequent IFRT after initial chemotherapy. Thirteen of the 65 patients received the front-line ASCT after RCHOP. Twelve patients received RCHOP alone.
  
  
  RESULTS
  Thirty two of the 40 patients who received the RCHOP followed by IFRT have complete remission (CR) or CRu (CR/unconfirmed). All patients have CR or CRu after the ASCT. The progression free survival (PFS) and the estimated overall survival (OS) rate at 5 years for 32 CR/CRu patients in the RCHOP followed by IFRT group were 57 and 65%, respectively, as compared to RCHOP/ASCT group who were 94 and 100%, respectively. Twelve patients who received RCHOP alone had the same PFS and OS rate as the 40 patients who received RCHOP/IFRT (5-year PFS:62 vs. 65%, p = 0.068; 5-year OS:57 vs. 67%, p = 0.058). For all 65 patients, the age-adjusted international prognostic index (aaIPI) score remained the only predictor of a worse outcome.
  
  
  CONCLUSIONS
  The PFS and OS rate of RCHOP/IFRT were found to be unsatisfied. RCHOP/ASCT showed a satisfactory PFS and OS rate.
authors.affiliation: a Department of Medical Oncology , Fudan University Shanghai Cancer Center , Shanghai , People's Republic of China.|b Department of Oncology , Shanghai Medical Collage, Fudan University , Shanghai , People's Republic of China.
authors.forename: Xiaojian
authors.initials: X
authors.lastname: Liu
authors.affiliation: c Department of Gastrointestinal Medical Oncology , Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy of Tianjin , Tianjin , People's Republic of China.
authors.forename: Ting
authors.initials: T
authors.lastname: Deng
authors.affiliation: d Department of Medical Oncology , Shanghai Pudong Hospital, Fudan University Pudong Medical Center , Shanghai , People's Republic of China.
authors.forename: Xianzhi
authors.initials: X
authors.lastname: Guo
authors.affiliation: a Department of Medical Oncology , Fudan University Shanghai Cancer Center , Shanghai , People's Republic of China.|b Department of Oncology , Shanghai Medical Collage, Fudan University , Shanghai , People's Republic of China.
authors.forename: Ye
authors.initials: Y
authors.lastname: Guo
authors.affiliation: a Department of Medical Oncology , Fudan University Shanghai Cancer Center , Shanghai , People's Republic of China.|b Department of Oncology , Shanghai Medical Collage, Fudan University , Shanghai , People's Republic of China.
authors.forename: Leiping
authors.initials: L
authors.lastname: Wang
authors.affiliation: a Department of Medical Oncology , Fudan University Shanghai Cancer Center , Shanghai , People's Republic of China.|b Department of Oncology , Shanghai Medical Collage, Fudan University , Shanghai , People's Republic of China.
authors.forename: Jian
authors.initials: J
authors.lastname: Zhang
authors.affiliation: a Department of Medical Oncology , Fudan University Shanghai Cancer Center , Shanghai , People's Republic of China.|b Department of Oncology , Shanghai Medical Collage, Fudan University , Shanghai , People's Republic of China.
authors.forename: Zuguang
authors.initials: Z
authors.lastname: Xia
authors.affiliation: a Department of Medical Oncology , Fudan University Shanghai Cancer Center , Shanghai , People's Republic of China.|b Department of Oncology , Shanghai Medical Collage, Fudan University , Shanghai , People's Republic of China.
authors.forename: Quanling
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: a Department of Medical Oncology , Fudan University Shanghai Cancer Center , Shanghai , People's Republic of China.|b Department of Oncology , Shanghai Medical Collage, Fudan University , Shanghai , People's Republic of China.
authors.forename: Kai
authors.initials: K
authors.lastname: Xue
authors.affiliation: a Department of Medical Oncology , Fudan University Shanghai Cancer Center , Shanghai , People's Republic of China.|b Department of Oncology , Shanghai Medical Collage, Fudan University , Shanghai , People's Republic of China.
authors.forename: Junning
authors.initials: J
authors.lastname: Cao
authors.affiliation: e Department of Hematology , Shanghai Tenth People's Hospital, Tongji University School of Medicine , Shanghai , People's Republic of China.
authors.forename: Jumei
authors.initials: J
authors.lastname: Shi
authors.affiliation: a Department of Medical Oncology , Fudan University Shanghai Cancer Center , Shanghai , People's Republic of China.|b Department of Oncology , Shanghai Medical Collage, Fudan University , Shanghai , People's Republic of China.
authors.forename: Xiaonan
authors.initials: X
authors.lastname: Hong
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D064592:Autografts; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000401:mortality / Q000628:therapy*; D008297:Male; D008479:Mediastinal Neoplasms / Q000401:mortality / Q000628:therapy*; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D012189:Retrospective Studies; D000069283:Rituximab / Q000008:administration & dosage*; D033581:Stem Cell Transplantation; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: Chemotherapy; front-line autologous stem-cell transplantation; lymphoma; mediastinal; radiation